Please login to the form below
Glybera
This page shows the latest Glybera news and features for those working in and with pharma, biotech and healthcare.
Bluebird puts €1.57m price on gene therapy Zynteglo
Zynteglo won't be the first ever 1m plus gene therapy launched in Europe - that distinction went to UniQure's rare disease treatment Glybera, which was launched in 2012.
Latest news
-
UniQure gets speedy US review for Huntington’s gene therapy
a-year Glybera back in 2012.
-
J&J bolsters gene therapy unit with $100m MeiraGTx deal
In Europe, the first approved gene therapy – UniQure’s Glybera – was launched way back in 2012 but was withdrawn five years later for commercial reasons.
-
AZ makes gene therapy move with 4DMT alliance
While enormously exciting gene therapy is still very much in its infancy, with just three commercial gene therapies approved in Europe and the US since UniQure’s Glybera made its debut
-
UniQure’s starts pivotal haemophilia B gene therapy trial
UniQure has the distinction of being the first company to get approval for a gene therapy in Europe, winning a green light for its Glybera (alipogene tiparvovec) product for the
-
Plasticell and London’s gene therapy pioneers to tackle manufacturing conundrum
Another gene therapy, UniQure’s Glybera, was withdrawn from the market after it flopped commercially – in part because of the excessive cost of manufacturing it.
More from news
Approximately 3 fully matching, plus 16 partially matching documents found.
Latest Intelligence
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
Gene therapy failures. The industry and Europe’s healthcare systems are wary of that magic one million threshold, thanks to the failure of the first ever gene therapy, UniQure’s Glybera.
-
Bluebird Bio: on the cusp of a gene therapy revolution
success. Europe has already seen two gene therapies approved but fail commercially – UniQure’s Glybera and GSK’s Strimvelis – and so Bluebird has to learn lessons on pricing and reimbursement and ... That means gene products hitting that Glybera
-
Health on instalment
Before being pulled from the European market for safety concerns and lack of uptake, pancreatic drug Glybera cost $1m a dose.
-
Rare diseases: meeting the challenge
Glybera, the expensive gene therapy developed for a small subset of patients with the rare familial lipoprotein lipase deficiency (LPLD). ... The company’s chief executive Matthew Kapusta said simply: “Glybera’s usage has been extremely limited and
-
Pharma deals in April 2015
Following Glybera's approval in Europe for lipoprotein lipase deficiency (LPLD), uniQure, the gene therapy pioneer has announced an exclusive strategic collaboration with Bristol Myers Squibb (BMS) for its lead candidate ... Glybera's $1m cost per
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest appointments
-
Basilea's Hans Christian Rohde takes up commercial role at uniQure
In his new role at Netherlands-based uniQure he will be tasked with helping the company commercialise Glybera, which last month became the first gene therapy to be approved in the ... Glybera treats patients with the inherited disease lipoprotein lipase
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Solaris Health looks at the gene therapy revolution
There has already been one notable disappointment. In 2017 uniQure pulled its gene therapy, Glybera (alipogene tiparvovec) for the rare inherited disorder lipoprotein lipase deficiency (LPLD) from Europe after 5 years,
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Account Director, Healthcare Communications
-
Salary TBC
- Account Director - Medical Communications - London / South East
-
Excellent Salary and Benefits on offer
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
-
Account Director – UK Office
-
Excellent salary and benefits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...
-
Excellent Daily Rate
- Account Director – London based Medical Communications Agency
-
Excellent Remuneration Package
Subscribe to our email news alerts
- GSK hires Merck KGaA exec to lead US pharma business
- Novartis chooses internal replacement for US pharma president role
- AZ, Merck’s Lynparza scores market-expanding clinical success
- Senators attack Novartis over 'unconscionable' handling of Zolgensma data
- Boris Johnson announces fast-track immigration plans for top scientists
- Lilly psoriasis drug beats J&J's Tremfya in head-to-head trial
- Blended Intelligence
- Planning a pharma exhibition stand? You must read this!
- Leaked no-deal Brexit document forecasts widespread shortages
- AbbVie scores FDA approval for arthritis treatment upadacitinib
- Novo Nordisk shareholder revolt reaches Europe
- BMS buoyed by FDA approval of Celgene’s myelofibrosis drug
PMHub
OUTiCO
Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...
Latest intelligence
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
- The relevance of patient perspectives to value
- Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
- How is the NHS Long-term Plan being put into action?
- Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
Quick links
Infographics
